Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pyridoxal phosphate

Drug Profile

Pyridoxal phosphate

Alternative Names: Avastrem; Cardoxal; MC-1; Pyridoxal 5'-phosphate; Tardoxal

Latest Information Update: 15 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medicure
  • Class Coenzymes; Ischaemic heart disorder therapies; Picolines; Small molecules
  • Mechanism of Action Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seizures
  • New Molecular Entity Yes
  • Available For Licensing Yes - Drug-induced dyskinesia

Highest Development Phases

  • Phase II Drug-induced dyskinesia
  • Preclinical Seizures
  • Discontinued Lipid metabolism disorders; Myocardial infarction; Reperfusion injury; Stroke

Most Recent Events

  • 12 Jul 2019 Pyridoxal phosphate is still in phase II trials for Drug-induced dyskinesia in Canada and India (Medicure website; July 2019)
  • 24 Jun 2015 Phase-II develoment for Drug-induced dyskinesia is ongoing in the US and Canada
  • 18 Aug 2014 Pyridoxal phosphate is available for licensing for Tardive dyskinesia as of 18 Aug 2014. http://www.medicure.com
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top